Literature DB >> 25363344

The transcription factor ETS1 in lymphomas: friend or foe?

Monica Testoni1, Elaine Yee Lin Chung, Valdemar Priebe, Francesco Bertoni.   

Abstract

ETS1 is a member of the ETS family of transcription factors, which contains many cancer genes. ETS1 gene is mapped at 11q24.3, a chromosomal region that is often the site of genomic rearrangements in hematological cancers. ETS1 is expressed in a variety of cells, including B and T lymphocytes. ETS1 is important in various biological processes such as development, differentiation, proliferation, apoptosis, migration and tissue remodeling. It acts as an oncogene controlling invasive and angiogenic behavior of malignant cells in multiple human cancers. In particular, ETS1 deregulation has been reported in diffuse large B-cell lymphoma, in Burkitt lymphoma and in Hodgkin lymphoma. Here, we summarize the function of ETS1 in normal cells, with a particular emphasis on lymphocytes, and its possible role as an oncogene or tumor suppressor gene in the different mature B cell lymphomas.

Entities:  

Keywords:  BLIMP1; ETS1; diffuse large B-cell lymphoma; lymphoma and Hodgkin disease; transcription factor

Mesh:

Substances:

Year:  2015        PMID: 25363344     DOI: 10.3109/10428194.2014.981670

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

Review 1.  Signatures of DNA target selectivity by ETS transcription factors.

Authors:  Gregory M K Poon; Hye Mi Kim
Journal:  Transcription       Date:  2017-03-16

2.  Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.

Authors:  Alexandra Nagy; Aparna Bhaduri; Nahid Shahmarvand; Jahanbanoo Shahryari; James L Zehnder; Roger A Warnke; Tariq Mughal; Siraj Ali; Robert S Ohgami
Journal:  Blood Adv       Date:  2018-03-13

3.  Multi-omics approach identifies germline regulatory variants associated with hematopoietic malignancies in retriever dog breeds.

Authors:  Jacquelyn M Evans; Heidi G Parker; Gerard R Rutteman; Jocelyn Plassais; Guy C M Grinwis; Alexander C Harris; Susan E Lana; Elaine A Ostrander
Journal:  PLoS Genet       Date:  2021-05-13       Impact factor: 5.917

4.  Identification of biomarkers and construction of a microRNA‑mRNA regulatory network for clear cell renal cell carcinoma using integrated bioinformatics analysis.

Authors:  Miaoru Han; Haifeng Yan; Kang Yang; Boya Fan; Panying Liu; Hongtao Yang
Journal:  PLoS One       Date:  2021-01-12       Impact factor: 3.240

5.  In the Tumor Microenvironment, ETS1 Is an Oncogenic Immune Protein: An Integrative Pancancer Analysis.

Authors:  Zixuan Wu; Yanhui Jiang; Xuyan Huang; Minjie Cai; Kai Yuan; Peidong Huang; Zuhong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-15       Impact factor: 2.650

6.  The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS.

Authors:  Beata Grygalewicz; Renata Woroniecka; Grzegorz Rymkiewicz; Jolanta Rygier; Klaudia Borkowska; Aleksandra Kotyl; Katarzyna Blachnio; Zbigniew Bystydzienski; Beata Nowakowska; Barbara Pienkowska-Grela
Journal:  Am J Clin Pathol       Date:  2017-12-20       Impact factor: 2.493

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.